26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          In psychotic and mood disorders, immune alterations are hypothesized to underlie cognitive symptoms, as they have been associated with elevated blood levels of inflammatory cytokines, kynurenine metabolites, and markers of microglial activation. The current meta-analysis synthesizes all available clinical evidence on the associations between immunomarkers (IMs) and cognition in these psychiatric illnesses.

          Methods

          Pubmed, Web of Science, and Psycinfo were searched for peer-reviewed studies on schizophrenia spectrum disorder (SZ), bipolar disorder (BD), or major depressive disorder (MDD) including an association analysis between at least one baseline neuropsychological outcome measure (NP) and one IM (PROSPERO ID:CRD42021278371). Quality assessment was performed using BIOCROSS. Correlation meta-analyses, and random effect models, were conducted in Comprehensive Meta-Analysis version 3 investigating the association between eight cognitive domains and pro-inflammatory and anti-inflammatory indices (PII and AII) as well as individual IM.

          Results

          Seventy-five studies ( n = 29,104) revealed global cognitive performance (GCP) to be very weakly associated to PII ( r = −0.076; p = 0.003; I 2 = 77.4) or AII ( r = 0.067; p = 0.334; I 2 = 38.0) in the combined patient sample. Very weak associations between blood–based immune markers and global or domain-specific GCP were found, either combined or stratified by diagnostic subgroup (GCP x PII: SZ: r = −0.036, p = 0.370, I 2 = 70.4; BD: r = −0.095, p = 0.013, I 2 = 44.0; MDD: r = −0.133, p = 0.040, I 2 = 83.5). We found evidence of publication bias.

          Discussion

          There is evidence of only a weak association between blood-based immune markers and cognition in mood and psychotic disorders. Significant publication and reporting biases were observed and most likely underlie the inflation of such associations in individual studies.

          Related collections

          Most cited references154

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

          The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.
            Bookmark
            • Record: found
            • Abstract: not found
            • Book: not found

            Cochrane Handbook for Systematic Reviews of Interventions

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

              Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness exacerbation. We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information and the reference lists of identified studies. Forty studies met the inclusion criteria. Effect sizes were similar for studies of acutely relapsed inpatients (AR) and first-episode psychosis (FEP). Interleukin (IL)-1β, IL-6, and transforming growth factor-β (TGF-β) appeared to be state markers, as they were increased in AR and FEP (p < .001 for each) and normalized with antipsychotic treatment (p < .001, p = .008, and p = .005, respectively). In contrast, IL-12, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and soluble IL-2 receptor (sIL-2R) appeared to be trait markers, as levels remained elevated in acute exacerbations and following antipsychotic treatment. There was no difference in IL-6 levels between stable medicated outpatients and control subjects (p = .69). In the cerebrospinal fluid, IL-1β was significantly decreased in schizophrenia versus controls (p = .01). Similar effect sizes in AR and FEP suggest that the association between cytokine abnormalities and acute exacerbations of schizophrenia is independent of antipsychotic medications. While some cytokines (IL-1β, IL-6, and TGF-β) may be state markers for acute exacerbations, others (IL-12, IFN-γ, TNF-α, and sIL-2R) may be trait markers. Although these results could provide the basis for future hypothesis testing, most studies did not control for potential confounding factors such as body mass index and smoking. Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                manuel.morrens@uantwerpen.be
                Journal
                Mol Psychiatry
                Mol Psychiatry
                Molecular Psychiatry
                Nature Publishing Group UK (London )
                1359-4184
                1476-5578
                28 April 2022
                28 April 2022
                2022
                : 27
                : 8
                : 3237-3246
                Affiliations
                [1 ]GRID grid.5284.b, ISNI 0000 0001 0790 3681, Faculty of Medicine and Health Sciences, , Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, ; Antwerp, Belgium
                [2 ]Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Centre Duffel, Duffel, Belgium
                [3 ]GRID grid.5284.b, ISNI 0000 0001 0790 3681, Faculty of Medicine and Health Sciences, , Nursing and obstetrics, University of Antwerp, ; Antwerp, Belgium
                [4 ]GRID grid.411326.3, ISNI 0000 0004 0626 3362, University Hospital Brussels, Brussels Health Campus, ; Jette, Belgium
                [5 ]GRID grid.462410.5, ISNI 0000 0004 0386 3258, INSERM U955, Equipe Psychiatrie Translationnelle, ; Créteil, France
                [6 ]GRID grid.484137.d, ISNI 0000 0005 0389 9389, Fondation FondaMental, ; Créteil, France
                [7 ]GRID grid.412116.1, ISNI 0000 0001 2292 1474, AP-HP, Hôpitaux Universitaires Henri Mondor, , DHU Pepsy, Pôle de Psychiatrie et d’Addictologie, ; Créteil, France
                [8 ]GRID grid.410511.0, ISNI 0000 0001 2149 7878, Université Paris Est Créteil, Faculté de Médecine, ; Creteil, France
                Author information
                http://orcid.org/0000-0003-4559-3666
                http://orcid.org/0000-0002-2642-5774
                http://orcid.org/0000-0001-5473-3697
                Article
                1582
                10.1038/s41380-022-01582-y
                9708549
                35484245
                b0db1fb9-571c-4522-883d-cb9abafe4f59
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 10 February 2022
                : 11 April 2022
                : 12 April 2022
                Categories
                Systematic Review
                Custom metadata
                © The Author(s), under exclusive licence to Springer Nature Limited 2022

                Molecular medicine
                depression,schizophrenia,bipolar disorder,diagnostic markers
                Molecular medicine
                depression, schizophrenia, bipolar disorder, diagnostic markers

                Comments

                Comment on this article